The novel coronavirus (COVID-19) pandemic announced by the World Health Organization in March 2020 has brought new tasks to the medical community that require immediate solutions. Recent studies have shown that invasive aspergillosis associated with coronavirus infection caused by COVID-19 often aggravates the course of the disease and leads to death. The article presents a clinical case of acute invasive aspergillosis in a COVID-19 patient with chronic somatic pathology but no risk factors for developing invasive pulmonary aspergillosis. The disease was progressing rapidly and led to a fatal outcome.Conclusion. In the case presented, invasive pulmonary aspergillosis was diagnosed with the help of histological examination of autopsy material.
The analysis of bronchial asthma prevalence in the Omsk region
SummaryAn analysis of bronchial asthma prevalence in the Omsk region based on findings of statistical reports and questionings has been presented in the article. Asthma prevalence in the Omsk region is as high as 1.044 % per 100 000 population and is expected to grow by 28 % during the next 5 years. Key words: asthma, prevalence, epidemiology.
РезюмеВ статье представлен анализ заболеваемости и распространенности бронхиальной астмы (БА) среди населения Омской обл. на основа нии данных статистических отчетов и анкетирования. Сделан прогноз динамики общей заболеваемости БА на ближайшие 5 лет. Ключевые слова: бронхиальная астма, заболеваемость, эпидемиология.
На основании ретроспективного анализа 1 121 протокола патологоанатомических исследований в крупном промышленном центре Юга
Западной Сибири изучена распространенность хронической обструктивной болезни легких и бронхиальной астмы. Установлено, что
58,8 % умерших имели морфологические проявления хронических заболеваний органов дыхания, сопровождающихся бронхиальной
обструкцией.
Idiopathic pulmonary fibrosis (IPF) is the most common clinical variant of idiopathic interstitial pneumonia. Pathophysiology of IPF involves recur rent damage of the alveolar epithelium with fibroblast excessive proliferation as aberrant reparative activity of the lung interstitium. Currently, a treat ment approach to this disease has been revised. Given new knowledge on pathogenesis of IPF, an international evidence based clinical guideline published in 2015 recommends antifibrotic agents as the basic therapy of IPF. The only antifibrotic agent registered in Russia is niintedanib. A clin ical case of IPF with the first experience of therapy with nintedanib in Omsk region has been reported in the article. Key words: idiopathic pulmonary fibrosis, antifibrotic agents, nintedanib.For citation: Akhmedov V.A., Petrov D.V., Gaus O.V., Ovsyannikov N.V., Kochetov A.M., Mashurov M.V., Moiseenko F.P. An experience of therapy with nintedanib in patients with idiopathic pulmonary fibrosis. Russian Pulmonology. 2016; 26 (6): 766-769 (in Russian).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.